Clinical Trials · NCT06426446

Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

Name: Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

UnknownN/ASemaglutide

Phase: N/A
Recruitment status: Unknown
Sponsor: Assistance Publique - Hôpitaux de Paris
Enrollment: 80
Start date: Jun 2024
Locations: 1 site, France
Primary endpoint: The relative difference in weight loss achieved at 6 months of treatment at the maximum tolerated dose ((weight after 6 months of treatment at the maximum tolerated dose - baseline weight) / baseline weight)

View Semaglutide compound reference